Twist Biosciences’ artificial intelligence (AI)-based drug discovery revenue nearly tripled in fiscal year 2026, however, the company did not raise its $100 million target for that segment in fiscal year 2027.
AI drug discovery was the company’s fastest-growing area, with full-year revenue of approximately $59.1 million, up 175 percent year over year from $21.5 million in fiscal year 2025.
Total revenue in fiscal Q4 was $126.6 million, up 28 percent from $99.0 million a year ago, beating the consensus Wall Street estimate of $123.6 million.
DNA Synthesis and Protein Solutions revenue was $61.0 million in the fourth quarter, up 33 percent from $46.0 million, and $221.9 million for the full year, up 32 percent year over year. NGS Applications revenue was $65.7 million in the fourth quarter, up 24 percent from $53.0 million, and $237.5 million for the full year, up 14 percent.
Twist’s net loss for the quarter was $20.6 million, or $0.32 per share, compared with a loss of $27.1 million, or $0.45 per share, a year ago, beating the consensus Wall Street estimate of $0.38 loss per share.
R&D expenses were $17.0 million in the fourth quarter, flat from a year ago. SG&A expenses rose to $74.7 million from $63.8 million a year ago.
Full-year revenue was $459.4 million, up 22 percent from $376.6 million a year ago. The company shipped products to approximately 4,100 customers and produced approximately 1.3 million genes, up from approximately 938,000 the year prior.
Net loss for the year was $130.2 million, or $2.08 per share, compared to $77.7 million a year ago. The prior-year figure included a $48.8 million gain on the sale of a business.
Full-year R&D expenses were $71.8 million, down from $80.3 million a year ago while SG&A rose to $301.2 million from $247.0 million a year ago.
Twist ended the quarter with approximately $582.0 million in cash, cash equivalents, and short-term investments.